SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the fourth cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with advanced prostate cancer who are relapsed or refractory to approved androgen receptor pathway... Read More

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc . (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer. Oncternal’s President and CEO, James Breitmeyer, M.D., Ph.D. will join Oppenheimer Senior Research... Read More

Third dosing cohort fully enrolled for our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the second quarter of 2024 Encouraging response signal at initial dose level in our ongoing Phase 1/2 study for ONCT-808, our ROR1-targeting... Read More

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2023 financial results after the U.S. financial markets close on Thursday, March 7, 2024. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide... Read More

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal’s President and Chief Executive Officer will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February... Read More

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science. The award will be made on February 1, 2024 under Oncternal’s 2021... Read More

SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the fourth patient has now been enrolled into its Phase 1/2 study of ONCT-534, its dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are relapsed or refractory to... Read More

SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that its board of directors (Board) has approved a 1-for-20 reverse stock split of the company's common stock. The reverse stock split will become effective at 12:01 a.m. Eastern time on January 8, 2024. The company's... Read More

SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager. The award will be made on January 2, 2024 under Oncternal’s 2021 Employment Inducement Incentive... Read More

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today updated the status of its dose escalation/dose expansion Phase 1/2 Study ONCT-808-101, evaluating the company’s ROR1-targeting autologous CAR T cell therapy ONCT-808 for the treatment of patients with relapsed or refractory... Read More

The first patient was dosed in our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors Additional patients were treated in our ongoing Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory... Read More

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets close on Thursday, November 9, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business... Read More

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients... Read More

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB). Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal’s next steps in the clinical... Read More

SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor. “The dosing of the first patient with ONCT-534 is an important... Read More

SAN DIEGO, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate Cancer SAB is comprised of distinguished academic and industry leaders in the prostate cancer field, which will advise Oncternal as it... Read More

Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor signaling inhibitors Dosed the first patient in our Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma Cash runway... Read More

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2023 financial results after the U.S. financial markets close on Thursday, August 10, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business... Read More

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration (FDA), for a Phase 1/2 dose escalation study of ONCT-534, a novel dual-action androgen receptor inhibitor (DAARI), in patients with... Read More

SAN DIEGO, June 30, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Yisrael Katz, M.D. who is joining Oncternal as VP, Clinical Development. The award will be made on July 1, 2023 under Oncternal’s 2021 Employment Inducement Incentive... Read More

SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-808, the company’s ROR1 targeting autologous CAR T cell therapy. “We are excited to announce the first patient, who had... Read More

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Dr. James Breitmeyer, Oncternal’s President and Chief Executive Officer will present at the 2023 Jefferies Healthcare Conference. 2023 Jefferies Healthcare Conference Date: Wednesday, June 7, 2023 at 4:30pm (ET) in... Read More

Phase 1/2 study initiated for ONCT-808, our autologous CAR-T targeting ROR1-expressing hematologic malignancies, with initial clinical data expected in late 2023 Final IND-enabling studies completed for ONCT-534, our novel dual-action androgen receptor inhibitor (DAARI), with expected IND submission in mid-2023 Cash runway extended into 2025, with $54.3 million in cash, cash equivalents and short-term investments and no debt... Read More

SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2023 financial results after the U.S. financial markets close on Thursday, May 4, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive... Read More

SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that two key industry opinion leaders and management will participate in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR-T Cell Therapy in Hematological Malignancies and Solid Tumors on Tuesday, April 18,... Read More

Zilovertamab Phase 3 Study ZILO-301 and Phase 1/2 Study CIRM-0001 to be closed based on dynamically changing therapeutic landscape Cash runway extended to 2025, enabling initial clinical data readouts for both ONCT-808, ROR1-tageting CAR T for patients with aggressive lymphomas, and ONCT-534, novel AR inhibitor for patients with resistant mCRPC Management to host webcast today at 5:00 pm ET SAN DIEGO, April 03, 2023 (GLOBE... Read More

SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal as Head of IT. The award will be made on April 3, 2023 under Oncternal’s 2021 Employment Inducement Incentive Award Plan, which... Read More

Encouraging and improving interim Phase 1/2 study results for zilovertamab plus ibrutinib in patients with MCL and CLL, including those with mutated TP53 and/or del(17p), presented at ASH in December 2022 Zilovertamab global Phase 3 registrational Study ZILO-301 for the treatment of patients with MCL initiated Phase 1/2 study for ONCT-808, our autologous CAR-T program targeting ROR1-expressing hematologic malignancies,... Read More

SAN DIEGO, March 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2022 financial results after the U.S. financial markets close on Thursday, March 9, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to... Read More

SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Yelena Tsabur, who joined Oncternal as Associate Clinical Trial Manager. The award was made on March 1, 2023 under Oncternal’s 2021 Employment Inducement... Read More

SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Jennifer Neumann, who joined Oncternal as Director, Clinical Data Management. The award was made on February 1, 2023 under Oncternal’s 2021 Employment Inducement... Read More

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Jill DeSimone to its board of directors. “We are thrilled to have Jill join the Oncternal board of directors. Jill’s accomplishments building a multi-billion dollar oncology business in the U.S. are a... Read More

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. The awards were made on January 3, 2023 under Oncternal’s 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity... Read More

Updated MCL and CLL data from the ongoing Phase 1/2 study of zilovertamab and ibrutinib are encouraging and continue to improve over prior reporting The ORR of 89% and CR rate of 43% for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to the historical ORR of 66% and CR rate of 20% for ibrutinib monotherapy Median PFS and OS have not been reached after a median follow up of 19.5 months for... Read More